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Abstract  
Ebola virus (EBOV) infection results in severe disease and in some cases 
lethal haemorrhagic fever. The infection is directed by seven viral genes that 
encode nine viral proteins.  By definition viruses are obligate intracellular 
parasites and require aspects of host cell biology in order to replicate their 
genetic material, assemble new virus particles and subvert host cell anti-viral 
responses. Currently licenced antivirals are targeted against viral proteins to 
inhibit their function.  However, experience with treating HIV and influenza 
virus demonstrates that resistant viruses are soon selected.  An emerging 
area in virology is to transiently target host cell proteins that play critical pro-
viral roles in virus biology, especially for acute infections.  This has the 
advantage that the protein being targeted is evolutionary removed from the 
genome of the virus.  Proteomics can aid in discovery biology and identify 
cellular proteins that may be utilised by the virus to facilitate infection.  This 
work focused on defining the interactome of the EBOV nucleoprotein and 
identified that cellular chaperones, including HSP70, associate with this 
protein to promote stability.  Utilisation of a mini-genome replication system 
based on a recent Makona isolate demonstrated that disrupting the stability 
of NP had an adverse effect on viral RNA synthesis. 
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Ebola virus, nucleoprotein, label free proteomics, HSP70, inhibitor, 
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Introduction 
 
A new variant of Ebola virus (EBOV), Ebola-Makona, has been responsible 
for causing a large sustained viral outbreak in West Africa (2014-
2015).  During the course of the crisis several experimental therapies and 
vaccines have been trialled, with some success, but overall this has 
illustrated the long lack of development of therapeutic strategies for EBOV. 
An emerging area in virology is the repurposing of inhibitors (normally used 
in human medicine) that disrupt the functioning of cellular proteins critical for 
the biology of such obligate intracellular parasites.  These inhibitors have 
distinct advantages in that they may have passed regulatory challenges for 
application in human health.  The identification of such critical cellular 
proteins for virus biology can be achieved through proteomic approaches to 
investigate viral/host protein-protein interactions.  In many cases this is 
facilitated by the use of an EGFP trap.  This technique has proved a versatile 
tagging strategy for immune-precipitation on a variety of different viral 
proteins with disparate functions, such as RNA dependent RNA 
polymerases1, interferon antagonists (including EBOV VP24)2; 3 and proteins 
interacting with viral RNA4; 5. 
 
EBOV has a negative sense RNA genome that is encapsidated by the virally 
encoded nucleoprotein (NP).  The N-terminal region of NP is thought to be 
important for RNA binding via its interaction with the phosphodiester 
backbone of the RNA.6  When the NP binds to the viral RNA genome it forms 
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a highly stable NP-RNA complex structure (the RNP).  This complex along 
with the viral protein 30 (VP30), the viral protein 35 (VP35) and the RNA-
polymerase RNA dependent (L) form the polymerase complex7, and these 
four viral proteins when expressed in cells, can replicate and transcribe 
EBOV RNA. This has been exploited in the development of plasmid based 
mini-genome systems that faithfully recapitulate EBOV RNA synthesis in the 
absence of infectious virus.8 Thus opening the study of the function of the 
four viral proteins, viral RNA and also high throughput screening at 
containment level 2 (CL2).  This work targeted NP to determine whether it 
interacted with host cell proteins, what these proteins were and how these 
might function in the biology of NP. 
 
In order to comprehensively define the cellular interactome of EBOV NP a 
high-affinity co-immunoprecipitation coupled to a label free mass 
spectrometry-based approach was used. Using conservative selection 
criteria, approximately 150 cellular proteins were identified that had a high 
probability of interacting with NP. These included the heat shock protein 70 
(HSP70) and members of the protein chaperone family.  Inhibition of HSP70 
function resulted in degradation of NP suggesting a role for HSP70 in 
modulating the stability of the protein.  This interactome of EBOV NP was 
also compared to the interactome of Reston virus (RESTV) NP.  This virus is 
a member of the Ebola virus genera and reported as non-pathogenic in 
humans. 
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To assess the effect of inhibiting HSP70 on the synthesis of EBOV RNA, a 
mini-genome system was developed based on the EBOV Makona isolate, 
taken from the 2014-2015 West African outbreak.  This mini-genome system 
recapitulated the essential stages of virus replication and transcription and 
expressed a luciferase reporter gene under the control of viral 
replication/transcription signals, and can be used to investigate viral genetics 
and screen inhibitory compounds to both viral (and cellular) proteins.9  
Perturbations to replication and/or transcription would result in alterations in 
the abundance and hence activity of luciferase, which can be easily assayed.  
The four viral proteins essential for encapsidation of viral RNA and replication 
and transcription (L, VP35, VP30 and NP) were expressed as codon 
optimized proteins from support plasmids. The data presented in this work 
indicated that amount of luciferase produced by the mini-genome system 
decreased in cells treated with the HSP70 inhibitor compound VER-155008 
compared to untreated cells, therefore the synthesis of EBOV RNA was 
reduced by inhibition of HSP70. These results suggest that HSP70 may play 
an important role for the EBOV virus replication probably by providing 
stability to NP. 
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Experimental procedures 
 
Construction of plasmids that express EBOV NP fused to EGFP. 
A codon optimized cDNA sequence for the ORF for EBOV (NCBI reference 
sequence number: NP_066243.1) and RESTV (NCBI reference sequence 
number: NP_690580.1) were cloned into the pEGFP-C1 and pEGFP-N1 
plasmids to generate NP with C-terminal EGFP tag (NP-EGFP) or N-terminal 
EGFP tag (EGFP-NP). Once cloned, the plasmids and the insert integrity 
were confirmed by sequencing. 
 
Plasmids used for the EBOV Makona mini-genome system. 
The mini-genome system for EBOV (Makona strain), expressing luciferase, 
used in this study, was designed following the mini-genome system model 
developed by Mülhgerber in 1999.8 The EBOV isolate H.sapiens-
wt/GIN/2014/Makona-Gueckedou-C07 complete genome (NCBI sequence 
number KJ660347.2) sequence was used for the construction of the support 
plasmids. Furthermore, 50 sequences of EBOV isolates, characterised 
during this outbreak, were also used as a point of reference. 10 
 
Expression of NP and EGFP tag in HEK 293T cells. 
Human embryonic kidney 293 (HEK 293T) cells were grown in 'XOEHFFR¶V
PRGLILHG (DJOH¶V PHGLXP '0(0 6LJPD $OGULFK VXSSOHPHQWHG ZLWK 
fetal bovine serum (FBS; Sigma Aldrich) and 1% penicillin-streptomycin 
(Sigma Aldrich) at 37°C with 5% CO 2. In order to transfect HEK 293T cells, 
two 145cm2 dishes were seed with 4x106 cells 24 hours prior to transfection. 
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Calcium phosphate transfection was performed with 25.6µg of plasmid DNA 
for each plasmid; EGFP, EGFP-NP and NP-EGFP. Cells were harvested 24 
hr post transfection, lysed and co-immunoprecipitated using a GFP-Trap 
(Chromotek). 
 
NP-EGFP co-immunoprecipitation 
NP/EGFP fusion proteins and EGFP co-immunoprecipitations were done 
using a GFP-Trap_A (Chromotek) as described in previous publications.2 
Co-immunoprecipitated samples were then analysed using label free mass 
spectrometry. To investigate whether the interaction of NP with selected 
cellular proteins was mediated by RNA binding an RNAse treatment (15 units 
of RNAse (QIAGEN; 19101) was performed after the co-
immunoprecipitations the with GFP-Trap. 
 
Reverse co-immunoprecipitations 
Reverse co-immunoprecipitations for the cellular proteins; chaperon HSP70 
and its co-chaperon BAG-2 were performed using 50ȝl of the immobilized 
recombinant protein G resin (Generon) and specific antibodies against 
HSP70 (Abcam; ab2787) and BAG-2 (Abcam; ab47106). Reverse co-
immunoprecipitation for EGFP-NP and NP-EGFP was done using an 
EBOV/NP Ab (IBT bioservices, 01-012); and on EGFP only as a negative 
control. The reverse co-immunoprecipitations were performed as described 
before..2 For western blot analysis the elution step was done in 100ȝl of 
2xSDS-sample buffer (120mM Tris/Cl pH6.8; 20% glycerol; 4%SDS, 0.04% 
bromophenol blue; 10% E-mercaptoethanol) 
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Label free Mass Spectrometry and bioinformatics analysis. 
Label free proteomic analysis was performed as described previously for 
studying the interactome of EBOV VP242, the mass spectrometry analysis 
was performed in triplicate for EGFP-NP, NP-EGFP and EGFP. Once label 
free mass spectrometry results were processed, the Perseus software 
(MaxQuant) was used for the statistical analysis of the data.  This helped 
differentiate the background proteins (those cellular proteins that interact with 
EGFP or matrix alone), from interacting proteins (those cellular proteins that 
interact with either EBOV or RESTV EGFP-NP or NP-EGFP). LFQ Intensity 
values were analysed using a T-Test analysis with a p-value of 0.01; a 
volcano plot graphic and tables were generated showing the statistical 
significant proteins, i.e. those proteins that had the highest probability of 
interacting with either EBOV or RESTV NP. 
 
Western blot analysis 
After the co-immunoprecipitation or reverse co-immunoprecipitation, western 
blot was performed as described previously. Antibodies used included 
EBOV/NP (IBT bioservices; 0301-012), GFP (Santa Cruz Biotechnology; sc-
8334), DNAJA2 (Santa Cruz Biotechnology; sc-136515), BAG-2 (Abcam; 
ab47106), PCNA (Abcam; ab29), AIF (Abcam; ab32516), STAT1 (Abcam; 
ab3987), HSP70 (Abcam; ab2787), HSP90 (Abcam; ab1429). After three 
washes, blots were incubated with appropriate HRP secondary antibody 
diluted in blocking buffer at a 1:2000 for 1 hour at room temperature. Blots 
then were developed using enhanced chemiluminescent reagent (BioRad) 
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and detected using a BioRad Imaging system. 
 
Luciferase assay and luciferase expression from the EBOV Makona 
mini-genome system in BSR-T7 cells. 
BSR-T7 cells were grown in DMEM(Sigma-Aldrich) with 10% FBS(Sigma-
Aldrich) plus 1X Glutamax (Invitrogen) and 600 Pg/ml of G418(Life 
technologies) added at every second passage (stock at 100 mg/ml, add 90 Pl 
to 15ml of medium in a T75 flask). BSR-T7 cells are derived from BHK-21 
cells. These were used in this experiment for their ability to continuously 
express T7 polymerase. For transfection of a 24-well dish (Appleton woods), 
8x104 cells were seeded overnight to achieve a desired cell density of 
approximately 90%. Lipofectamine 2000 (Invitrogen) was used to transfect 
the BSR-T7 cells with the complete (+L) luciferase-based or incomplete (-L) 
luciferase based EBOV Makona mini-genome system. In order to do this 
different amounts of the mini-genome plasmids (miniG-Luc 0.5 Pg, N 0.25 Pg, 
VP35 0.125 Pg, VP30 0.125 Pg and L 0.125 Pg or no L) plus a co-transfected 
³FRQWURO´ SODVPLG H[SUHVVLQJ Renilla luciferase; Promega; 
pGL4.74[hRluc/TK]) reporter that was used as an internal baseline control. 
The transfection experiments were done using 2.0Pl of Lipofectamine 2000 
DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQstructions.  
 
Luciferase was then visualised by western blot analysis, using an antibody 
against Firefly luciferase (Abcam; ab185923), and by the Dual-Luciferase£ 
Reporter Assay System (Promega; E1910) DFFRUGLQJ WR WKHPDQXIDFWXUHU¶V
instructions. 
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Inhibition of HSP70 using VER-15508 and its effect on the replication 
and transcription of EBOV. 
Transfection of the EBOV Makona mini-genome system using BSR-T7 cells 
was done as described before. Then, at 4h post-transfection, Lipofectamine 
was removed by changing the medium which contained different 
concentrations of the HSP70 inhibitor (VER-155008). VER-15508 was diluted 
in DMSO to make a stock solution of 10mM; then the stock solution was 
diluted in medium and add to the cells in different concentrations (5ȝ0, 
10ȝ0, 20ȝ0, 40ȝ0, 60ȝ0, 80ȝ0 and 100 ȝ0). Cells were then incubating at 
37Cq, 5% CO2 for 24 h before the analysis. Luciferase detection was then 
done using a western blot analysis and a Dual-Luciferase£ Reporter Assay 
System (Promega; E1910). 
 
Inhibition of HSP70 using VER-15508 and its effect on NP expression. 
For NP transfection, 8x104 BSR-T7 cells were seeded overnight in a 24-well 
multi well dish (Appleton woods), to achieve desired cell density of 
approximately 90%. Lipofectamine 2000 (Invitrogen) was used to transfect 
the BSR-T7 cells as was described before, 0.8 Pg of EGFP, EGFP-NP or 
NP-EGFP DNA plasmid were add into 50 Pl of OPTI-MEM (Invitrogen) while 
2.0Pl of Lipofectamine 2000 was add into another 50Pl of OPTI-MEM 
(Invitrogen). Lipofectamine 2000 was then incubate for 5 min at room 
temperature in the OPTI-MEM media and then the mixture of Lipofectamine 
2000 plus the EGFP, EGFP-NP or NP-EGFP plasmids was added; the 
mixture was then mix and incubated for 20 min at room temperature and 
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finally added dropwise onto cells maintained in 1 ml of growth media (DMEM 
with 10% FBS). At 4h post-transfection, Lipofectamine was removed by 
changing medium which contained different concentrations of the VER-
15508 (10ȝ0, 20ȝ0, 40ȝ0, 60ȝ0 and 80ȝ0). Then, the cells were left 
incubating at 37Cq, 5% CO2 for 24 h before the analysis. NP-EGFP detection 
was done using a western blot analysis using a highly specific EGFP 
antibody (Santa Cruz Biotechnology; sc-8334) and an EBOV NP antibody 
(IBT bioservices; 0301-012).  
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Results 
 
Expression of EBOV NP in 293T cells  
To determine the cellular interacting partners of EBOV NP a high affinity 
EGFP co-immunoprecipitation (co-IP) coupled to a label-free mass 
spectrometry approach was used (Figure 1A). The target protein, NP, was 
expressed as an EGFP-fusion protein; this technique has been shown to 
improve the sensitivity and also to allow the discrimination between specific 
and non-specific interaction to the target proteins.11; 12 The gene encoding for 
a codon optimized EBOV 13ZDVFORQHGHLWKHUDW WKH¶RU¶RIan EGFP 
gene (NP-EGFP and EGFP-NP), creating a contiguous open read framing 
and the expression of a fusion protein. The expression of EGFP at either the 
N or C-terminal of NP was to mitigate for any steric hindrance caused by the 
presence of EGFP. 
 
The fusion proteins were overexpressed in cells, and proteins were extracted 
from lysed cells and used for co-immunoprecipitation. To identify the 
potential interacting partners of NP, the eluate or bound fraction was then 
analysed by label free mass spectrometry. To reduce the false positive rate, 
EGFP alone was also expressed in 293T cells as a control. The 293T cells 
were selected for this study due to their high efficiency for calcium phosphate 
mediated transfection, annotation of the human protein database and 
because this cell line is permissive for EBOV infection.13; 14; 15 
 
Protein expression was confirmed in 293T cells using immunofluorescence; 
the efficiency of transfections for all plasmids was approximately 70% (Figure 
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1B). Interacting partners for NP were then co-immunoprecipitated using an 
EGFP-Trap. After co-immunoprecipitation, both input and elution (or bound) 
samples were analysed using western blot; a protein corresponding to the 
molecular weight of NP-EGFP (131 kDa) was detected using and anti-EGFP 
Ab and an anti-NP antibody (Figure 1C). Label free mass spectrometry and 
quantitative proteomics was then used to distinguish between the EBOV NP-
EGFP and EBOV NP-EGFP interactomes from the control (EGFP alone), 
which led to the identification of possible interacting partners for NP. 
 
Identification of the potential cellular interacting partners of EBOV NP 
Potential interacting partners for NP were identified by label free mass 
spectrometry; a statistical analysis approach was used in order to help 
distinguish the NP interacting partners from the background non-specific 
binding proteins (those cellular proteins that bind to the binding matrix or 
EGFP alone);11; 12 the experiment was repeated three times. Approximately 
1050 proteins were identified by mass spectrometry in the co-
immunoprecipitation.  After statistical analysis approximately 150 proteins 
were filtered to have a high probability (95% of confidence) of interacting with 
NP. The statistical analysis of the mass spectrometry results and all data 
sets were calculated using the Perseus program algorithm (Max Plank 
Institute).  A t-Test analysis was done with a p-value <0.01.  Additionally, 
proteins identified with a single peptide were removed. In the t-Test analysis 
each group of proteins detected in the MS for all the constructs that express 
NP was compared to the control (plasmid expressing EGFP alone).  
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The data was then organized in the form of volcano plots (Figure 2); in these 
volcano plots the logarithmic ratio of protein intensities (x-axis) was plotted 
against the negative logarithmic p-values of the t test (y-axis). The proteins 
that were significant or had a high probability of interacting with NP had a 
high log ratio and therefore are located in the upper right quadrant. Each dot 
outside the volcano represented a protein with a high probability of 
interacting with NP; those proteins inside the volcano are potential 
background binding proteins or proteins that do not interact with NP. For 
EGFP-NP, 124 cellular proteins were identified as interacting partners with 
statistical significance while for NP-EGFP, 151 cellular proteins were 
identified as interacting partners. Of these, 109 cellular proteins were 
common to EGFP-NP and NP-EGFP, suggesting a similar interactome for 
both constructs. Unique proteins were also identified that bound only to either 
EGFP-NP (15 cellular proteins) or to NP-EGFP (42 cellular proteins (Tables 
2A and 2B). The cellular proteins that were unique to each construct had 
generally lower fold enrichment compared to those that interacted with both 
constructs. One exception was the stress-induced phosphoprotein 1 (STIP1). 
These unique proteins may be reflective of forming association with NP 
proximal to the position of the EGFP-tag, which may sterically hinder the 
interaction.  Selected proteins with a higher probability of interacting with NP 
were selected for follow on studies (Tables 1A and 1B). A complete list of the 
possible interacting partners for EGFP-NP and NP-EGFP are shown in 
Tables S1 and S2 in the supplementary data section. 
 
Validation of EBOV NP interactions.  
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Selected cellular targets identified as possible interacting partners of NP 
were then investigated by western blot analysis on repeat pull downs using 
the EGFP trap. Reverse immunoprecipitations were also performed to 
confirm the interaction between selected cellular proteins and the NP/EGFP 
fusion proteins. The selected cellular targets investigated in the immune-
precipitations of NP were HSP70, HSP90, DNAJA2, PCNA, AIF and BAG2.  
These targets were selected due to their common functions (the protein 
chaperones), probability of interacting with NP (proteins with high binding 
ratio), and the availability of small molecules inhibitors. The presence of 
these proteins was confirmed by western blot (Figure 3A). Whole cell lysate 
(input) and eluate (bound) sample from co-immunoprecipitations analysis 
(GFP-Trap) were separated by 1D-SDS PAGE, proteins were then 
transferred in western blot and detected using a primary antibody against 
each selected protein.  The data indicated that HSP70, HSP90, DNAJA2, 
PCNA, AIF and BAG2 associated with EGFP-NP and NP-EGFP. The cellular 
protein STAT1 was used as a negative control for the pull downs as it was 
not identified by LC-MS/MS, but was present in the input fractions (Figure 
3A). 
 
NP is a RNA binding protein, therefore to investigate whether these 
interactions were protein-protein rather than protein-RNA mediated, input 
samples were treated with RNAse before co-immunoprecipitation (Figure 
3B). After immunoprecipitation of the treated input samples, the bound 
samples were analysed again by western blot using specific antibodies 
against selected proteins HSP70, BAG2 and DNAJA2 (Figure 3C). The 
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selected target proteins were found in the bound fraction after the RNAse 
treatment, which indicated that the interactions were not potentially mediated 
by RNA. However, DNAJA2 showed a reduction in the amount of protein in 
the pull down after the RNAse treatment (Figure 3C), indicating its interaction 
with NP was (part) RNA-mediated. 
 
To further validate the mass spectrometry results and the potential 
interacting partners of NP, reverse co-immunoprecipitation was performed 
against selected cellular targets where antibody combinations allowed. 
These targets were NP (as a positive control), HSP70 and BAG2. NP was 
overexpressed in 293T cells and then cellular proteins were extracted.  
Immunoprecipitations were then performed using protein G beads and 
specific monoclonal antibodies against HSP70 or BAG2. The bound samples 
obtained from the reverse co-immunoprecipitations were then analysed by 
western blot, which confirmed the presence of NP (Figure 4A) and the 
interaction with HSP70 and BAG2 (Figure 4B and 4C, respectively).  As a 
result of these interactions we hypothesized that HSP70 and other 
chaperones were important for viral RNA synthesis by promoting the stability 
of the N protein. 
 
Interaction with HSP70 maintains the stability of NP. 
To test the hypothesis that the function of HSP70 was critical for maintaining 
the stability of NP, a small molecular inhibitor compound was selected that 
prevents the interaction of HSP70 with the target protein,16; 17.  This 
compound was used to treat cells expressing EBOV NP.  The small molecule 
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has been used previously to study the interaction between HSP70 and other 
viral proteins.1; 18; 19.  Therefore, increasing concentrations of VER-155008 
was added to cells expressing either EGFP-NP, NP-EGFP or EGFP. 
Western blot was used to evaluate the abundance of EGFP, EGFP-NP or 
NP-EGFP in the presence of increasing concentrations of VER-155008 
(Figure 5).  The data indicated that as the concentration of VER-155008 
increased, the abundance of the NP fusion protein decreased in comparison 
to GAPDH and EGFP (note equal amounts of protein were compared from 
each treatment condition). Only the highest concentration of VER-155008 
had a negative impact on EGFP alone. Given the known activity of VER-
155008 in disrupting the chaperone function of HSP70, we postulate that 
HSP70 is involved in maintaining the stability of NP (when expressed as an 
EGFP fusion protein). 
 
The stability of wild type NP is dependent on HSP70 and disruption 
negatively impacts viral RNA synthesis 
We hypothesized that disruption of HSP70 would negatively impact wild type 
NP and have a concomitant effect on viral RNA synthesis.  To dissect this 
precise function and recapitulate this safely at CL-2, a mini-genome system 
for EBOV was developed (based on EBOV sequence from the recent West 
African outbreak). This was designed following the methodology developed 
to study other variants of EBOV.8 The EBOV mini-genome system used in 
this study consisted of four support plasmids that expressed codon optimized 
L, VP30, VP35 and NP with a mini-genome plasmid expressing an artificial 
viral genomic RNA that contained the leader and trailer sequences from 
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EBOV with the luciferase (luc) gene as a reporter gene (Figure 6A).  
Expression of viral mRNAs were under the control of a T7 promoter and 
translation of the resulting proteins facilitated by an IRES.   The amount of 
each plasmid used for the mini-genome system to produce luciferase was 
optimized (Table 3), as well as the time for the expression of luciferase to 
obtain the maximum signal-to-noise ratio.  Validation of the system was 
confirmed by examining the expression of luciferase in the absence and 
presence of the L protein, where we predicted that absence of this protein 
would result in no luciferase.  This was confirmed by comparing luciferase 
activity (Figure 6B) and the amount of luciferase by western blot (Figure 6C) 
between transfected cells with the three other support plasmids but either 
without and with the L protein.  Thus luciferase protein/activity is dependent 
on synthesis of its mRNA by the viral components of the mini-genome 
system.  Disruption of these components would negatively impact luciferase 
production which can then be quantified.  
 
We hypothesized that disruption of HSP70 with VER-155008 in the context of 
the mini-genome system would result in the decreased abundance of NP and 
a reduction in the amount of luciferase, due to the involvement of NP in viral 
RNA synthesis.  To test this, cells expressing the mini-genome were treated 
with increasing concentrations of VER-155008 which would impact the 
stability/abundance of the EGFP-tagged NPs. The amount of NP, luciferase 
and GAPDH was compared for each treatment condition and to a control.  
These were untreated cells either not expressing or expressing the L with the 
rest of the mini-genome components (Figure 7A).  The activity of luciferase in 
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these different treatment conditions was also measured (Figure 7B).  Similar 
to the observations with the EGFP-tagged NPs, increasing concentrations of 
VER-155008 negatively impacted the abundance of native NP and also 
luciferase expression but had no effect on GAPDH.  Also, the activity of 
luciferase was decreased in the mini-genome system in the presence of 
increasing concentrations of VER-155008.  Taken together this data 
indicated that the stability of NP was dependent on functioning HSP70.  
When NP was disrupted, synthesis of the luciferase mRNA in the mini-
genome system was adversely effected. 
 
The interaction with protein chaperones is conserved in other members 
of the Ebola virus family. 
We hypothesized that if protein chaperones are important for the biology of 
EBOV NP then association with these proteins would be conserved in other 
members of the Ebola virus family.  In terms of pathogenic outcome in 
humans, RESTV is most different from EBOV, in that no disease has been 
reported in humans that have been found to been potentially infected with the 
virus.7 EBOV and RESTV NPs share 68% identity at the amino acid level.  
To investigate the interactome of RESTV NP, the protein was expressed in 
cells as either a N or C-terminal EGFP fusion protein. After mass 
spectrometry and data processing 113 cellular proteins were found to interact 
with RESTV EGFP-NP and 134 proteins were found to interact with RESTV 
NP-EGFP (Tables S3 and S4). From those, 92 were common for both 
constructs while 21 cellular proteins interacted with EGFP RESTV-NP and 42 
proteins with RESTV NP-EGFP (Tables S5 and S6).  Examination of the 
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resulting volcano plots (Figure 8) indicated that RESTV NP also interacted 
with same protein chaperones as EBOV NP. Western blot was also used to 
independently validate the interactions between selected cellular proteins 
and RESTV NP (Figure 9). 
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Discussion 
 
There is little information available regarding the interactions of EBOV NP 
with cellular proteins. Elucidation of these interactions will provide a better 
understanding of the function of NP in virus biology and will also indicate 
potential cellular targets for potential novel antivirals that target the function 
of host proteins crucial for virus biology.1; 2; 3; 4 To elucidate the cellular 
interactome of EBOV NP, a pull down approach coupled to mass 
spectrometry was used.  This identified ~150 cellular proteins that potentially 
associated with EBOV NP and included protein chaperones. Interactions 
were confirmed with both repeat forward and reverse pulldowns.  Some of 
these proteins, such as HSP90, have previously been proven to be important 
for the Ebolavirus biology.20 Several novel interactions were also found, 
including; HSP70, BAG2, DNAJA2, AIF and PCNA. These cellular factors 
may be common to NPs encoded by other negative strand RNA viruses that 
belong, as does EBOV, to the order Mononegavirales. For example, 
chaperones have been shown to associate with the NP of Rabies virus and 
Measles virus21; 22, thus indicating a general pattern. Certainly, the cellular 
interactome of the NP from another Ebola virus (RESTV) was similar to that 
of EBOV (Table S1, S2, S3, S4). 
 
Due to its emerging importance in viral biology as illustrated by in depth work 
on Dengue virus18, HSP70 was selected for further functional analysis using 
a specific small molecule inhibitor. HSP70 is involved in several cellular 
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processes including protein folding, regulation of the stress response, and 
control of the activity of regulation proteins.23 Due to its multi-functional 
nature, HSP70 may also play an important role in viral survival strategies24, 25; 
26
 such as avoiding degradation of certain viral proteins21; 27, that may be 
expressed in large quantities or have complex folding; viral envelope 
protein/folding maturation27 among others. These factors make chaperones 
essential for the stability and function of viral proteins and also can provide 
new possible drug target therapy against viruses.20; 29; 30  In this study, VER-
155008, a small molecule inhibitor against HSP70, was used to inhibit the 
function of HSP70 and its concomitant effects on EBOV biology in the 
context of a mini-genome system was evaluated. The targeted inhibition of 
HSP70 may concomitantly affect the stability of NP, but not necessarily the 
interaction between HSP70 and NP.  
Conclusions 
Treatment of cells expressing NP with VER-155008 showed a reduction in 
the abundance NP both in the context of the fusion proteins used for IP but 
also in the context of the mini-genome system. Suggesting that the 
chaperone activity of HSP70 was responsible for maintaining the stability of 
NP.  In this latter system, the abundance and activity of luciferase in the 
EBOV mini-genome system decreased with increasing concentrations of the 
HSP70 inhibitor, suggesting a negative effect on the replication 
and/transcription of EBOV RNA. Similar results were found for HRSV 
(another member of the Mononegavirales family); where treatment with VER-
155008 showed a reduction in the replication of HRSV1 and also for Dengue 
virus where small doses of VER-155008 were demonstrated to affect virus 
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replication and therefore progeny virus production.18 Overall, the data 
provides further evidence that protein chaperones play important roles in 
positively contributing to virus biology, and that this can be disrupted using a 
small molecule inhibitor. 
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Table S1 and S2: Complete list of cellular proteins that have a higher 
probability of forming protein-protein interactions with EBOV/NP.  
Shown are candidate proteins identified using the (S1) EGFP-EBOV/NP, 
(S2) EBOV/NP-EGFP fusion proteins and identified using label free 
quantitative proteomics. 
 
Table S3 and S4: Complete list of cellular proteins that have a higher 
probability of forming protein-protein interactions with RESTV/NP.  
Shown are candidate proteins identified using the (S1) EGFP-RESTV/NP, 
(S2) RESTV/NP-EGFP fusion proteins and identified using label free 
quantitative proteomics. 
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Figure 1. Expression of EBOV NP in 293T cells. (A) Schematic 
representation of the methodology used in this study. 293T cells were grown 
in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin at 
37°C with 5% CO 2. Two 145cm2 dishes were seeded with 4x106 cells 24 
hours prior to calcium phosphate transfection with 25.6 µg of plasmid DNA 
encoding EGFP, EGFP-NP and NP-EGFP respectively. 24 hours post 
transfection the cells were harvested, lysed and immunoprecipitated using a 
GFP-Trap (Chromotek).  Label free Mass Spectrometry analysis on the 
eluted samples was then carried out. (B) Expression of EGFP-NP, NP-EGFP 
and the control EGFP in 293T cells was confirmed by immunofluorescence 
using confocal microscopy; the panels show that expression of the four 
constructs were similar, however EGFP-NP showed a higher and more 
uniform expression in cells than NP-EGFP. (C) Analysis of the pull down 
products using a western blot confirmed the presence of EGFP-NP, NP-
EGFP and the control EGFP with the expected molecular weight.  
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Figure 2. Volcano plots representing results of the MS and the statistical 
analysis for EBOV NP.  The pull down and label free mass spectrometry was 
done in triplicate. In these volcano plots the dots outside the volcano 
represents the potential protein interacting partners for (A) EGFP-NP and (B) 
NP-EGFP. For any potential protein interaction partner with NP the value of 
its abundance co-immunoprecipitated with any of EBOV NP was compared 
to the value of co-immunoprecipitated with the control (EGFP alone).  
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Figure 3. Validation of possible interacting partners of EBOV NP. (A) 
The presence of selected cellular proteins in the pulldowns identified in the 
label free mass spectrometry analysis was confirmed by western blot 
analysis.  This used both whole cell lysate or input samples (I) and the eluate 
samples (E) for the three different constructs. Specific monoclonal antibodies 
against HSP90, HSP70, AIF, DNAJA2, PCNA, BAG2 and STAT-1 were used 
to detect their respective proteins. (B) RNase treatment was confirmed by 
using agarose gel electrophoresis on samples that had been either left 
untreated or treated with RNase (as indicated by ± or +, respectively). (C) 
Invesitgation whether EBOV NP interactions were RNA mediated using 
western blot on RNAase untreated and treated extracts. Specific monoclonal 
antibodies against HSP70, DnaJA2 and BAG2 were used to detected the 
target proteins.  
  
 35 
Figure 4. Validation of EBOV NP interactions using reverse 
immunoprecipitation. To further validate the interaction results, reverse 
immunoprecipitations were preformed against selected cellular proteins 
identified by the label free mass spectrometry and subsequent statistical 
analysis.  Specific antibodies against EBOV NP (as a positive control), 
HSP70 and BAG2 were used for the reverse pull down. Then, the presence 
of the protein complex NP-EGFP was confirmed using western blot analysis 
and a specific antibody against EGFP (for reverse pull down for EBOV-NP); 
and an EBOV/NP antibody in for the reverse pull down for HSP70 and BAG2.  
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Figure 5. Effect of VER-155008 on the abundance of EBOV NP in BSR-T7 
cells. Different concentrations of the HSP70 inhibitor (VER-155008) were 
tested to determine the effect of different concentrations of the drug on the 
abundance of NP. Decreased expression of NP was observed when the cells 
were treated with VER-155008. 
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Figure 6 Optimization of amount of plasmids for the mini-genome 
system. (A) Schematic representation of the mini-genome system. The 
EBOV (Makona) mini-genome system consists of five plasmids: four support 
plasmids that express the NP, VP30, VP35 and L; and the mini-genome 
plasmid which contains the leader and trailer sequences of EBOV (Makona 
strain) and has a sequences that encode luciferase as a reporter gene. (B) 
Measurement of luciferase expression using the Dual Luciferase assay 
(Promega). (C) Western blot of luciferase expressed by the mini-genome 
system at 24 and 48 hours; for the western blot analysis an antibody against 
Firefly Luciferase was used. 
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Figure 7. Effect of the HSP70 inhibitors in the replication and 
transcription of EBOV. A mini-genome system for Ebola virus that 
expressed luciferase was used to measure the effect of VER-155008 to 
determine the effect of this compound on the replication-transcription of 
EBOV RNA. (A) For the experiment with the mini-gnome system, seven 
different concentrations of VER-15508 were used for the inhibition 
experiment. The results of this experiment was analysed by western blot 
analysis using an antibody against Firefly Luciferase .(B) The Dual 
Luciferase Assay (Promega) was also used to measure the amount of 
Luciferase produced by the mini-genome system. The x-axis indicates the 
different concentration of compound used in the experiment; in the y-axis, the 
fold change of Luciferase expression compared to the control. The results of 
these experiments were confirmed the western blot analysis. 
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Figure 8. Volcano plot representing results of the MS and the statistical 
analysis for RESTV NP. The pull down and label free mass spectrometry 
was performed in triplicate. In these volcano plots the dots outside the 
volcano represents the potential protein interacting partners for (A) RESTV 
RESTV-NP and (B) RESTV NP-EGFP. For any potential protein interaction 
partner with NP the value of its abundance co-immunoprecipitated with any 
of RESTV NP was compared to the value of co-immunoprecipitated with the 
control (EGFP alone). 
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Figure 9. Validation of possible interacting partners of RESTV NP by 
western blot analysis. Confirmation of proteins detected in the label free 
mass spectrometry analysis by western blot analysis was done in the whole 
cell lysate or Input samples (I) and in the eluate sample (E) for the three 
different constructs. Specific monoclonal antibodies against HSP90, HSP70, 
AIF, DNAJA2, PCNA, BAG2 and STAT-1 were used to detect the respecitve 
proteins. An anti-EGFP antibody was used as a control to show the presence 
of the constructs RESTV EGFP-NP and RESTV NP-EGFP in the input and in 
the elution samples. 
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Table 1: Cellular proteins that have a higher probability of forming protein-protein interactions with EBOV/NP. Shown are 
candidate proteins identified using the (A) EBOV EGFP-NP, (B) EBOV NP-EGFP fusion proteins and identified using label free 
quantitative proteomics.  Protein identifier, protein name and gene names are indicated, total and unique peptides used to identify 
the protein are indicated.  The ±LogP value is a comparison of the cellular protein between the EBOV/NP pull down and EGFP, 
where the higher the number means the higher probability of interacting, and a threshold above 2.0 has been selected.  The t-test 
difference is the difference of the means of the intensities of the cellular proteins in the EBOV-NP pull down and EGFP. The 
percentage of sequence coverage of the protein identified using the peptides is indicated SC%.  The abundance (ppm) of the 
protein in an average human cell is listed ± data taken from the PaxDb: Protein Abundance Across Organisms database 
 
Table.1A: Significant proteins that interact with EGFP-EBOV/NP 
 
 Protein IDs Protein names Gene 
names 
Peptides Unique peptides 
-Log t-
test P 
value 
T-test Difference  
(EGFP-EBOV/NP 
vs EGFP) 
SC 
[%] 
Abundance 
(PPM) 
1 Q5JP53;P07437 Tubulin beta chain TUBB 42 8 1.3 7.3 78.4 1041 ppm 
2 Q13825;B4DYI6 Methylglutaconyl-CoA hydratase, 
mitochondrial 
AUH 8 8 4.7 6.9 28.0 27.3 ppm 
3 Q16342;F5H4V9 Programmed cell death protein 2 PDCD2 11 11 5.7 6.7 39.0 NA 
4 Q3ZCM7;F5H0I4 Tubulin beta-8 chain TUBB8 13 2 4.3 6.1 25.2 175 ppm 
5 P31689;B7Z5C0 DnaJ homolog subfamily A member 1 DNAJA1 25 25 3.2 5.9 63.5 15.2 ppm 
6 Q96EY1;I3L1T6 DnaJ homolog subfamily A member 3, 
mitochondrial 
DNAJA3 10 1 4.8 5.5 26.9 1.19 ppm 
7 P49411;H3BNU3 Elongation factor Tu, mitochondrial TUFM 23 23 3.0 5.4 59.7 991 ppm 
8 O43175;Q5SZU1 D-3-phosphoglycerate dehydrogenase PHGDH 33 33 2.8 5.4 64.4 100 ppm 
9 Q14257;F8WCY5 Reticulocalbin-2 RCN2 12 12 6.1 5.3 50.2 112 ppm 
10 Q9BUF5;K7ESM5 Tubulin beta-6 chain TUBB6 23 10 2.7 5.3 67.0 183 ppm 
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11 Q9BVA1 Tubulin beta-2B chain TUBB2B 36 1 4.4 5.2 73.9 543 ppm 
12 P30153;F5H3X9 Serine/threonine-protein phosphatase 2A 65 
kDa regulatory subunit A alpha isoform 
PPP2R1A 14 14 2.9 5.2 36.8 184 ppm 
13 P17987;E7ERF2 T-complex protein 1 subunit alpha TCP1 26 26 5.3 5.2 62.2 114 ppm 
14 Q9H7B4;B0QZ88 Histone-lysine N-methyltransferase SMYD3 SMYD3 7 7 4.4 5.2 17.5 NA 
15 Q10567;P63010 AP-1 complex subunit beta-1 AP1B1 13 13 2.7 5.0 13.8 127 ppm 
16 O95831;E9PMA0 Apoptosis-inducing factor 1, mitochondrial AIFM1 13 13 3.8 4.9 32.6 688 ppm 
17 K7EJL1;B4DDG7 AP-1 complex subunit mu-1 AP1M1 8 8 5.9 4.9 26.2 3.03 ppm 
18 H0YEN5;P15880 40S ribosomal protein S2 RPS2 10 10 2.7 4.7 49.7 131 ppm 
19 Q9BQE3;F5H5D3 Tubulin alpha-1C chain TUBA1C 37 2 2.4 4.5 76.8 691 ppm 
20 F5GZS6;J3KPF3 4F2 cell-surface antigen heavy chain SLC3A2 8 8 3.3 4.5 17.9 147 ppm 
21 P68363;A8MUB1 Tubulin alpha-1B chain;Tubulin alpha-4A 
chain 
TUBA1B 39 4 1.8 4.4 76.5 749 ppm 
22 Q9Y230;B3KQ59 RuvB-like 2 RUVBL2 28 28 2.4 4.3 74.7 23.4 ppm 
23 P56192;A6NC17 Methionine--tRNA ligase, cytoplasmic MARS 12 12 4.2 4.3 20.0 6.11 ppm 
24 P04843;B7Z4L4 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1 
RPN1 10 10 1.5 4.3 21.7 179 ppm 
25 Q9GZT9 Egl nine homolog 1 EGLN1 3 3 4.3 4.2 14.6 NA 
26 P85037;E9PM37 Forkhead box protein K1 FOXK1 8 6 3.1 4.1 11.5 NA 
27 O60884;H3BMW5 DnaJ homolog subfamily A member 2 DNAJA2 10 10 3.1 4.1 29.1 3.39 ppm 
28 P27824;B4DGP8 Calnexin CANX 17 17 1.1 4.1 34.3 1213 ppm 
29 B7Z9I1;Q5T4U5 Medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
ACADM 8 8 3.8 4.1 29.1 828 ppm 
30 P35613;R4GN83 Basigin BSG 3 3 5.6 4.1 12.5 21.7 ppm 
31 P11177;C9J634 Pyruvate dehydrogenase E1 component 
subunit beta, mitochondrial 
PDHB 9 9 2.7 4.1 27.9 393 ppm 
32 H7C4H2;Q9Y5M8 Signal recognition particle receptor subunit 
beta 
SRPRB 6 6 2.6 4.0 46.2 17.5 ppm 
33 P08238;Q58FF7 Heat shock protein HSP 90-beta HSP90AB1 35 26 1.7 4.0 49.0 693 ppm 
34 Q9Y5J9;G3XAN8 Mitochondrial import inner membrane 
translocase subunit Tim8 B 
TIMM8B 6 6 4.6 3.9 60.2 NA 
35 Q9BSD7;Q5TDF0 Cancer-related nucleoside-triphosphatase NTPCR 7 7 4.4 3.9 56.8 4.71 ppm 
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Table.1B: Significant proteins that interact with EBOV/NP-EGFP. 
 Protein IDs Protein names Gene 
names 
Peptides Unique peptides 
-Log P 
value 
t-test Difference 
(EBOV/NP-EGFP 
vs EGFP) 
SC [%] Abundance (PPM) 
1 P31948;G3XAD8 Stress-induced-phosphoprotein 1 STIP1 58 58 4.2 8.1 74 120 ppm 
2 Q14257;F8WCY5 Reticulocalbin-2 RCN2 12 12 5.3 7.4 50.2 112 ppm 
3 Q5JP53;P07437 Tubulin beta chain TUBB 42 8 1.4 6.9 78.4 1041 ppm 
4 B4E2W0;P55084 Trifunctional enzyme subunit beta, 
mitochondrial;3-ketoacyl-CoA thiolase 
HADHB 21 21 3.9 6.9 51.5 777 ppm 
5 P31689;B7Z5C0 DnaJ homolog subfamily A member 1 DNAJA1 25 25 2.9 6.7 63.5 15.2 ppm 
6 O95816;B4DXE2 BAG family molecular chaperone regulator 2 BAG2 15 15 3.7 6.7 77.3 5.24 ppm 
7 P08238;Q58FF7 Heat shock protein HSP 90-beta HSP90AB1 35 26 2.4 6.6 49 693 ppm 
8 Q3ZCM7;F5H0I4 Tubulin beta-8 chain TUBB8 13 2 5.3 6.5 25.2 175 ppm 
9 P40939;B4DYP2 Trifunctional enzyme subunit alpha, 
mitochondrial;Long-chain enoyl-CoA 
hydratase 
HADHA 16 16 4.8 6.3 30.9 1175 ppm 
10 P49411;H3BNU3 Elongation factor Tu, mitochondrial TUFM 23 23 3.9 6.2 59.7 991 ppm 
11 P17066;P48741 Heat shock 70 kDa protein 6 HSPA6 19 2 5.5 6.2 20.5 104 ppm 
12 Q9BUF5;K7ESM5 Tubulin beta-6 chain TUBB6 23 10 3.9 6.0 67 183 ppm 
13 Q9BVA1 Tubulin beta-2B chain TUBB2B 36 1 5.4 5.8 73.9 543 ppm 
14 Q16342;F5H4V9 Programmed cell death protein 2 PDCD2 11 11 4.1 5.8 39 NA 
15 P17987;E7ERF2 T-complex protein 1 subunit alpha TCP1 26 26 3.9 5.7 62.2 114 ppm 
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16 P34932 Heat shock 70 kDa protein 4 HSPA4 23 21 4.9 5.7 37.5 46.3 ppm 
17 O95831;E9PMA0 Apoptosis-inducing factor 1, mitochondrial AIFM1 13 13 5.5 5.7 32.6 688 ppm 
18 P50502;H7C3I1 Hsc70-interacting protein;Putative protein 
FAM10A5 
ST13 14 14 5.0 5.6 34.4 179 ppm 
19 O60884;H3BMW5 DnaJ homolog subfamily A member 2 DNAJA2 10 10 4.3 5.5 29.1 3.39 ppm 
20 Q9Y5J9;G3XAN8 Mitochondrial import inner membrane 
translocase subunit Tim8 B 
TIMM8B 6 6 3.6 5.2 60.2 NA 
21 P11142;E9PKE3 Heat shock cognate 71 kDa protein HSPA8 68 24 3.1 5.2 73.1 1014 ppm 
22 O43175;Q5SZU1 D-3-phosphoglycerate dehydrogenase PHGDH 33 33 2.7 5.1 64.4 100 ppm 
23 Q9BQE3;F5H5D3 Tubulin alpha-1C chain TUBA1C 37 2 2.5 5.1 76.8 691 ppm 
24 Q96EY1;I3L1T6 DnaJ homolog subfamily A member 3, 
mitochondrial 
DNAJA3 10 1 3.7 5.0 26.9 1.19 ppm 
25 Q9UNE7;H3BS86 E3 ubiquitin-protein ligase CHIP STUB1 16 16 2.5 5.0 71 3.78 ppm 
26 P68363;A8MUB1 Tubulin alpha-1B chain;Tubulin alpha-4A 
chain 
TUBA1B 39 4 2.0 4.9 76.5 749 ppm 
27 P08107;E7EP94 Heat shock 70 kDa protein 1A/1B HSPA1A 74 45 3.2 4.9 84.9 389 ppm 
28 P62081;B5MCP9 40S ribosomal protein S7 RPS7 5 5 3.3 4.8 30.9 288 ppm 
29 P78527;E7EUY0 DNA-dependent protein kinase catalytic 
subunit 
PRKDC 19 19 3.7 4.7 6 12.6 ppm 
30 P07900;Q86U12 Heat shock protein HSP 90-alpha HSP90AA1 21 13 3.8 4.6 36.3 841 ppm 
31 P11177;C9J634 Pyruvate dehydrogenase E1 component 
subunit beta, mitochondrial 
PDHB 9 9 5.2 4.6 27.9 393 ppm 
32 Q9Y230;B3KQ59 RuvB-like 2 RUVBL2 28 28 3.5 4.6 74.7 23.4 ppm 
33 B4DX52;P25685 DnaJ homolog subfamily B member 1 DNAJB1 8 8 4.0 4.5 46.7 10.7 ppm 
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Table 2: Unique cellular proteins that form protein-protein interactions 
with EBOV EGFP-NP (A) or EBOV NP-EGFP (B). Shown are unique 
candidate proteins identified using the (A) EBOV EBOV-NP, (B) EBOV NP-
EGFP fusion proteins and identified using label free quantitative proteomics 
The ±LogP value is a comparison of the cellular protein between the 
EBOV/NP pull down and EGFP, where the higher the number means the 
higher probability of interacting, and a threshold above 2.0 has been 
selected.  The t-test Difference is the difference of the means of the 
intensities of the cellular proteins in the EBOV/NP pull down and EGFP.  
 
Table 2A 
EGFP-
EBOVNP 
Gene 
names 
Log t-test 
P value 
T-test Difference  
(EGFP-EBOV/NP vs 
EGFP) 
1 TUBA1C 2.4 4.5 
2 EGLN1 4.3 4.2 
3 MTA2 2.2 3.5 
4 AP1G1 3.7 3.4 
5 PGRMC1 1.5 3.2 
6 C1QBP 1.0 3.2 
7 SSBP1 2.0 3.2 
8 RBBP4 1.8 2.9 
9 EIF4A2 2.2 2.6 
10 TFRC 1.8 2.5 
11 SERPINH1 1.2 2.5 
12 TKT 4.2 2.3 
13 PPP2CA 3.0 2.2 
14 BCAP31 2.2 2.1 
15 VAT1 2.1 2.1 
 
  
 47 
Table 2B 
EBOV/NP 
EGFP 
Gene 
names 
Log P 
value 
t-test Difference 
(EBOV/NP-EGFP vs 
EGFP) 
1 STIP1 4.2 8.1 
2 HSPA6 5.5 6.2 
3 HSPA4 4.9 5.7 
4 ST13 5.0 5.6 
5 TUBA1C 2.5 5.1 
6 STUB1 2.5 5.0 
7 HSP90AA1 3.8 4.6 
8 DNAJB1 4.0 4.5 
9 DYNC1I2 3.7 4.2 
10 DNAJC7 4.0 4.0 
11 UBL4A 2.9 3.5 
12 HNRNPH1 2.4 3.3 
13 CALU 3.4 3.3 
14 PSMC3 3.2 3.3 
15 GLG1 4.0 3.2 
16 TIMM8A 4.4 3.1 
17 BAG6 1.7 3.0 
18 RPS3 1.4 3.0 
19 RPS24 1.3 2.9 
20 RPS10 3.5 2.8 
21 SGTA 4.8 2.8 
22 RPL13A 3.3 2.8 
23 UQCRC2 3.0 2.8 
24 ATP1B3 4.6 2.7 
25 B2M 3.2 2.7 
26 SDF2L1 1.5 2.7 
27 SLC25A3 2.8 2.6 
28 RPS5 1.2 2.6 
29 RPL37A 3.5 2.6 
30 RPL18A 3.9 2.5 
31 RPS15A 1.1 2.5 
32 TUBB4A 3.2 2.5 
33 GNB2 2.4 2.4 
34 XPO1 2.7 2.3 
35 SAMHD1 1.8 2.2 
36 SRSF6 3.5 2.2 
37 EMD 2.3 2.2 
38 DNAJB6 2.3 2.2 
39 PSMC6 3.8 2.1 
40 HSPA5 2.7 2.0 
41 SPTLC1 2.7 2.0 
42 YTHDF2 3.6 2.0 
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Table 3. Optimization of amount of plasmids for the minigenome system. : Table showing the different concentrations used in 
order to optimize the expression of Luciferase for the miningenome system; several controls were used (columns 1 to 4) and also 
different concentration of plasmids were tried for the optimization; the condition number 9 was the best and therefore selected to the 
following experiments.  
 
 
EBOV Makona Minigenome 
(ug) 1 2 3 4 5 6 7 8 9 10 11 
Mini G 0 0.5 0.5 0 0.25 0.25 0.5 0.5 0.5 0.5 0.5 
N 0 0.25 0.25 0.25 0.125 0.25 0.125 0.25 0.25 0.25 0.25 
VP35 0 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 
VP30 0 0.125 0 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 
L 0 0 0.125 0.125 0.125 0.125 0.125 0.0625 0.125 0.25 0.5 
